Profound Medical Corp. (PROF) — SEC Filings
Profound Medical Corp. (PROF) — 50 SEC filings. Latest: 8-K (Apr 16, 2026). Includes 26 6-K, 17 8-K, 3 10-Q.
View Profound Medical Corp. on SEC EDGAR
Overview
Profound Medical Corp. (PROF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: On March 27, 2026, Profound Medical Corp. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes a press release, which is the primary document for this report. Specific financial figures or operational updates are not detailed in the provided
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Profound Medical Corp. is neutral.
Filing Type Overview
Profound Medical Corp. (PROF) has filed 17 8-K, 3 10-Q, 1 10-K, 26 6-K, 3 SC 13G/A with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PROF's 42 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 33 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $10,121,000 |
| Net Income | -$34,395,000 |
| EPS | -$1.14 |
| Cash Position | $24,826,000 |
Industry Context
Profound Medical Corp. operates in the medical technology sector, specifically focusing on minimally invasive treatments. The company's revenue growth, particularly in capital equipment, suggests increasing market acceptance of its technology. However, the competitive landscape in medical devices is intense, requiring continuous innovation and significant R&D investment.
Top Tags
filing (17) · press-release (16) · 6-K (7) · sec-filing (6) · 8-K (5) · foreign-private-issuer (4) · disclosure (3) · 8-k (3) · financial-condition (3) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $10.1M | Increased 55.6% for the nine months ended September 30, 2025, from $6.5M in 2024. |
| Net Loss | $34.4M | Widened for the nine months ended September 30, 2025, from $22.9M in 2024. |
| Cash Balance | $24.8M | Decreased significantly from $54.9M at December 31, 2024, raising going concern doubts. |
| Net Cash Used in Operating Activities | $31.6M | For the nine months ended September 30, 2025, indicating substantial cash burn. |
| Research and Development Expenses | $16.3M | Increased from $12.3M for the nine months ended September 30, 2024. |
| Selling, General and Administrative Expenses | $25.0M | Increased from $16.5M for the nine months ended September 30, 2024. |
| Basic and Diluted Net Loss Per Common Share (Q3 2025) | $0.26 | Lower than $0.38 in Q3 2024, but on a higher share count. |
| Basic and Diluted Net Loss Per Common Share (9M 2025) | $1.14 | Higher than $0.94 in 9M 2024, reflecting increased losses. |
| Common Shares Outstanding | 30,193,592 | As of November 13, 2025, up from 30,039,809 at December 31, 2024. |
| Cash | $35.195M | Decreased from $54.912M at Dec 31, 2024, highlighting significant cash burn. |
| R&D Expenses | $10.906M | Increased from $8.150M, reflecting continued investment in product development. |
| SG&A Expenses | $17.537M | Nearly doubled from $9.856M, indicating aggressive commercialization efforts. |
| Liquidity Horizon | 12 months | Expected period existing cash can fund operations, but dependent on assumptions. |
| Additional Financing Deadline | Q3 2026 | Company's ability to achieve strategic plans dependent on obtaining financing by this time. |
| Diluted Loss Per Share | $0.88 | Increased from $0.55 in prior year, reflecting higher net loss. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Profound Medical Corp. (PROF)?
Profound Medical Corp. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 26 6-K, 17 8-K, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PROF filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant sentiment is neutral.
Where can I find Profound Medical Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Profound Medical Corp. (PROF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Profound Medical Corp.?
Key financial highlights from Profound Medical Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PROF?
The investment thesis for PROF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Profound Medical Corp.?
Executive information for Profound Medical Corp. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Profound Medical Corp. stock?
Of PROF's 42 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 33 low-risk.
What are recent predictions and forward guidance from Profound Medical Corp.?
Forward guidance and predictions for Profound Medical Corp. are extracted from SEC filings as they are enriched.